SCHEMBL17817601

SCHEMBL17817601

CCCCCCCCCCCCNC(=O)C(=O)NCCCN1CCOCC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.68
KDM4E B2RXH2 1/20 0.68
GAA P10253 1/20 0.66
RAB9A P51151 1/20 0.63
ALDH1A1 P00352 1/20 0.61
POLB P06746 2/20 0.59
TP53 P04637 1/20 0.59
PAOX Q6QHF9 1/20 0.57
PKM P14618 1/20 0.56
HPGD P15428 1/20 0.55
DUSP3 P51452 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
KMT2A Q03164 3/20 0.54
TSHR P16473 1/20 0.54
MAPT P10636 1/20 0.54
HTT P42858 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MAPK1 P28482 1/20 0.54
HIF1A Q16665 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8587098 1.00 LMNA (0.68) LMNAKDM4EGAARAB9AALDH1A1
SCHEMBL7747980 0.92 LMNA (0.59) LMNAKDM4EGAARAB9AALDH1A1
SCHEMBL13655375 0.89 LMNA (0.84) LMNAKDM4EGAARAB9AALDH1A1
SCHEMBL8591441 0.85 ALDH1A1 (0.60) LMNAKDM4EGAAALDH1A1PAOX
SCHEMBL21998731 0.85 ALDH1A1 (0.60) LMNAKDM4EGAAALDH1A1PAOX
SCHEMBL9544143 0.85 ALDH1A1 (0.60) LMNAKDM4EGAAALDH1A1PAOX
SCHEMBL21999365 0.85 ALDH1A1 (0.60) LMNAKDM4EGAAALDH1A1PAOX
SCHEMBL21999366 0.85 ALDH1A1 (0.60) LMNAKDM4EGAAALDH1A1PAOX
SCHEMBL9633172 0.85 ALDH1A1 (0.60) LMNAKDM4EGAAALDH1A1PAOX
SCHEMBL11776407 0.85 ALDH1A1 (0.54) LMNAKDM4EGAARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3229811-B1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GRI BIO INC (US) 2021-02-24 EP disclosed
WO-2016094226-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GLYCOREGIMMUNE, INC. (US) 2016-06-16 WO disclosed
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS ALTIUM GROWTH FUND, LP 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS RXRA, RXRG, CX3CR1 LMNA 2135/4885KDM4E 812/4885GAA 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.